Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting, 51917-51918 [2016-18560]
Download as PDF
Federal Register / Vol. 81, No. 151 / Friday, August 5, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
2. Type of Information Collection
Request: New collection (Request for a
new OMB control number); Title of
Information Collection: The PACE
Organization (PO) Monitoring and Audit
Process in 42 CFR part 460; Use:
Historically, the Programs of AllInclusive Care for the Elderly (PACE)
audit protocols have been included in
the Medicare Advantage (MA) and
Medicare Part D audit protocol’s
information collection request (CMS–
10191, OMB 0938–1000). However, in
examining previous submissions, we do
not believe that including it with the
MA and Part D audit protocols allowed
for an accurate representation of the
PACE burden. Due to PACE audits being
substantially different from our MA and
Part D audits, we have separated the
PACE audit protocols from the MA and
Part D protocols and created this
information collection request which
seeks OMB approval under a new
control number.
POs are required to comply with all
PACE program requirements. The
growth of these PACE organizations
forced CMS to develop an audit strategy
to ensure we continue to obtain
meaningful audit results. As a result,
CMS’ audit strategy reflected a move to
a more targeted, data-driven and
outcomes-based audit approach. We
focused on high-risk areas that have the
greatest potential for participant harm.
CMS has developed an audit protocol
and will post it to the CMS Web site
each year for use by POs to prepare for
their audit. The data collected for audit
is detailed in this protocol and the exact
fields are located in the record layouts,
at the end of the protocol. In addition,
a questionnaire will be distributed as
part of our audit. This questionnaire is
also included in this package. Form
Number: CMS–10630 (OMB control
number: 0938–New); Frequency: Yearly;
Affected Public: Private sector (Business
or other for-profits and Not-for-profits
institutions); Number of Respondents:
72; Total Annual Responses: 72; Total
Annual Hours: 12,960. (For policy
questions regarding this collection
contact Caroline Zeman at 410–786–
0116.)
Dated: August 2, 2016.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2016–18662 Filed 8–4–16; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
17:42 Aug 04, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Cellular, Tissue, and Gene Therapies
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Cellular, Tissue, and
Gene Therapies Advisory Committee.
The general function of the committee is
to provide advice and recommendations
to the Agency on FDA’s regulatory
issues. At least one portion of the
meeting will be closed to the public.
DATES: The meeting will be held on
September 7, 2016, from 1 p.m. to 4
p.m.
SUMMARY:
FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993–0002.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Janie Kim or Denise Royster, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Silver
Spring, MD 20993–0002, 301–796–9016
or 240–402–8158, Janie.kim@
fda.hhs.gov or Denise.royster@
fda.hhs.gov; or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting. For those unable to attend in
person, the meeting will also be
available via Webcast. The Webcast will
be available at the following link:
https://collaboration.fda.gov/
ctgtac0916/.
ADDRESSES:
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
51917
SUPPLEMENTARY INFORMATION:
Agenda: On September 7, 2016, the
committee will meet by teleconference.
In open session, the committee will hear
updates of research programs in the
Gene Transfer and Immunogenicity
Branch, Division of Cellular and Gene
Therapies, Office of Cellular, Tissue,
and Gene Therapies, Center for
Biologics Evaluation and Research.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: On September 7, 2016,
from 1 p.m. to 2:20 p.m., the meeting is
open to the public. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 23, 2016.
Oral presentations from the public will
be scheduled between approximately
2:20 p.m. to 3:20 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before August
15, 2016. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 16, 2016.
Closed Committee Deliberations: On
September 7, 2016, from 3:20 p.m. to 4
p.m., the meeting will be closed to
permit discussion where disclosure
would constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)). The committee will discuss
reports of intramural research programs
and make recommendations regarding
personnel staffing decisions.
Persons attending FDA’s advisory
committee meetings are advised that the
E:\FR\FM\05AUN1.SGM
05AUN1
51918
Federal Register / Vol. 81, No. 151 / Friday, August 5, 2016 / Notices
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Janie Kim at
least 7 days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 1, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special
Medical Programs.
[FR Doc. 2016–18560 Filed 8–4–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Pediatric Master Protocols; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration (FDA), in collaboration
with the University of Maryland Center
of Excellence in Regulatory Science and
Innovation, is announcing a public
workshop titled, ‘‘Pediatric Master
Protocols’’. The objective of the
workshop is to discuss regulatory and
scientific concerns related to pediatric
master protocols and clinical trial
design considerations for these
protocols. In addition, applications of
pediatric master protocols to specific
pediatric therapeutic areas will be
presented.
SUMMARY:
The public workshop will be
held on September 23, 2016, from 8:30
a.m. to 4:30 p.m.
ADDRESSES: The public workshop will
be held at FDA’s White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993–
0002. Entrance for the public meeting
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
mstockstill on DSK3G9T082PROD with NOTICES
DATES:
VerDate Sep<11>2014
17:42 Aug 04, 2016
Jkt 238001
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
FOR FURTHER INFORMATION CONTACT:
Audrey Thomas, Office of Regulatory
Science and Innovation, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4220, Silver Spring,
MD 20993–0002, 301–796–3520,
Audrey.Thomas@fda.hhs.gov.
The
purpose of this public workshop is to
provide an opportunity for relevant
stakeholders including: Clinicians and
scientists from FDA and other
government Agencies, academia, nonprofit organizations, and industry to
discuss use of pediatric master protocols
for development of medical products for
children. Specifically, the workshop
will present the current status of
pediatric protocol development in the
United States, considerations for
pediatric protocol development
internationally, and development of
international consortia in this area.
Clinical trial design considerations and
the preliminary steps needed for
development of pediatric master
protocols, including the role of in vitro
diagnostic tests, will also be discussed.
Finally, examples of pediatric master
protocol development for medical
products with no, partial, and full
extrapolation of data from adults to
children will be presented. The
workshop will include two panel
sessions for interaction and discussion
among the speakers and attendees.
Agenda: The agenda is available at
https://www.fda.gov/ScienceResearch/
SpecialTopics/RegulatoryScience/
ucm507079.htm (FDA has verified the
Web site address, but FDA is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register).
Registration: There is a registration fee
to attend this public workshop inperson. Seats are limited and
registration will be on a first-come, firstserved basis. To register, please
complete registration online at https://
www.fda.gov/ScienceResearch/Special
Topics/RegulatoryScience/
ucm507079.htm (FDA has verified the
Web site address, but FDA is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register).
There will be no onsite registration. The
costs of registration, to attend in-person,
for different categories of attendees are
as follows:
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Category
Cost
Industry Representative ........
Nonprofit Organization and
Academic Other Than University of Maryland ............
University of Maryland, College Park and Baltimore ...
Federal Government .............
$50
50
0
0
Streaming Webcast of the Public
Workshop: This public workshop will
also be Webcast. There is no registration
fee for access to the workshop via the
Webcast, but registration is still
required. Information regarding
registration and access to the Webcast
link is available at https://www.fda.gov/
ScienceResearch/SpecialTopics/
RegulatoryScience/ucm507079.htm. If
you have never attended a Connect Pro
event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. (FDA has
verified the Web site addresses in this
document, but FDA is not responsible
for any subsequent changes to the Web
sites after this document publishes in
the Federal Register.)
Accommodations: Attendees are
responsible for their own hotel
accommodations. If you need special
accommodations while at FDA’s White
Oak Campus due to a disability, please
contact Shari Solomon at
Shari.Solomon@fda.hhs.gov at least 7
days in advance.
Dated: August 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–18555 Filed 8–4–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
National Mammography Quality
Assurance Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the National Mammography
Quality Assurance Advisory Committee.
The general function of the committee is
to provide advice and recommendations
to the Agency on FDA’s regulatory
SUMMARY:
E:\FR\FM\05AUN1.SGM
05AUN1
Agencies
[Federal Register Volume 81, Number 151 (Friday, August 5, 2016)]
[Notices]
[Pages 51917-51918]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18560]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
Cellular, Tissue, and Gene Therapies Advisory Committee; Notice
of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Cellular, Tissue, and Gene
Therapies Advisory Committee. The general function of the committee is
to provide advice and recommendations to the Agency on FDA's regulatory
issues. At least one portion of the meeting will be closed to the
public.
DATES: The meeting will be held on September 7, 2016, from 1 p.m. to 4
p.m.
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. Answers to commonly asked questions including information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: Janie Kim or Denise Royster, Center
for Biologics Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 301-
796-9016 or 240-402-8158, Janie.kim@fda.hhs.gov or
Denise.royster@fda.hhs.gov; or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in
the Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting. For those unable to attend in person, the meeting will
also be available via Webcast. The Webcast will be available at the
following link: https://collaboration.fda.gov/ctgtac0916/.
SUPPLEMENTARY INFORMATION:
Agenda: On September 7, 2016, the committee will meet by
teleconference. In open session, the committee will hear updates of
research programs in the Gene Transfer and Immunogenicity Branch,
Division of Cellular and Gene Therapies, Office of Cellular, Tissue,
and Gene Therapies, Center for Biologics Evaluation and Research.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: On September 7, 2016, from 1 p.m. to 2:20 p.m., the
meeting is open to the public. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Written submissions may be made to the contact person on
or before August 23, 2016. Oral presentations from the public will be
scheduled between approximately 2:20 p.m. to 3:20 p.m. Those
individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the general
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
August 15, 2016. Time allotted for each presentation may be limited. If
the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by August 16, 2016.
Closed Committee Deliberations: On September 7, 2016, from 3:20
p.m. to 4 p.m., the meeting will be closed to permit discussion where
disclosure would constitute a clearly unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of
intramural research programs and make recommendations regarding
personnel staffing decisions.
Persons attending FDA's advisory committee meetings are advised
that the
[[Page 51918]]
Agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Janie Kim at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: August 1, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special Medical Programs.
[FR Doc. 2016-18560 Filed 8-4-16; 8:45 am]
BILLING CODE 4164-01-P